Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy
- 148 Downloads
We would like to address several challenges that have arisen from the study by Sakai et al. , which are specifically summarized below.
Missing data from the article by Sakai et al. 
The PCV duration before the entry into the study
The duration of the aflibercept treatment prior to the start of triple therapy
The anatomical types of macular edema (diffuse/subretinal fluid/cystic changes within neurosensory retina/mixed type) at index date and at month 12
The proportion of patients with complete dry macula at the end of the study
The anatomical lesions of the PCV (serous and hemorrhagic detachments of the RPE and neurosensory retina, exudative changes, aneurismal polypoidal lesions with overlying atrophy of the pigment epithelium, abnormal branch vascular networks, vitreous hemorrhage, subretinal fibrosis, pigment epithelial hyperplasia, and atrophic degeneration) at baseline and at the...
Compliance with ethical standards
Conflict of interest
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures.
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
- 5.Călugăru D, Călugăru M (2017) Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Eur J Ophthalmol 27(3):107–108Google Scholar
- 9.Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMedGoogle Scholar